Key Details
Price
$59.25Last Dividend
$0.60Annual ROE
26.48%Beta
0.14Events Calendar
Next earnings date:
Feb 06, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Feb 02, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Oct 04, 2024Next split:
N/ARecent split:
Aug 07, 2001Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
We think that Bristol Myers Squibb stock (NYSE: BMY) is a more attractive choice in the pharmaceutical sector compared to Johnson & Johnson stock (NYSE: JNJ) due to its stronger outlook. BMY shares are currently valued at 8.3 times their expected earnings for 2025, while JNJ shares are at 14.7 times.
Investors frequently consider large pharmaceutical companies as a stable option for their portfolios. This is because these companies are believed to have reliable cash flows, which can help them grow in value consistently over time.
Bristol-Myers Squibb Company (NYSE:BMY) will be participating in the Jefferies London Healthcare Conference on November 19, 2024, at 4:30 AM ET. The company representatives include David Elkins, the CFO, along with another unidentified representative. Thank you all for joining us for this next discussion.
Bristol-Myers Squibb's stock has increased by over 25% in the last six months, showing strong advancements in its oncology and neuroscience divisions. In the third quarter of 2024, Yervoy's sales reached $642 million, which is a 10.9% rise compared to the same time last year and a 1.9% increase from the previous quarter. Additionally, on September 26, 2024, the company revealed the long-anticipated approval of Cobenfy for treating schizophrenia.
Yields have gradually increased since the Federal Reserve lowered interest rates in September.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--Bristol Myers Squibb has received a favorable opinion from the CHMP for the use of Opdivo® in combination with Yervoy® as a first-line treatment for adult patients with microsatellite instability.
On Thursday, Bristol Myers Squibb faced a $6.7 billion lawsuit that accuses the company of deceiving former Celgene shareholders by postponing federal approval for three drugs. This lawsuit comes just a month and a half after a federal judge unexpectedly threw out an earlier version of the case.
Bristol-Myers Squibb Company (NYSE:BMY) will participate in the Guggenheim Securities Inaugural Healthcare Innovation Conference on November 11, 2024, at 10:00 AM ET. The company will be represented by Samit Hirawat, the Executive Vice President and Chief Medical Officer, and Robert Plenge, the Executive Vice President and Chief Research Officer. Seamus Fernandez from Guggenheim will also be part of the conference call.
BMY has performed well over the last three months. Recently, the stock reached its highest point in a year.
In the third quarter of 2024, the biopharmaceutical industry began to recover, driven by growing investor confidence after the U.S. Federal Reserve lowered interest rates in September.
FAQ
- What is the primary business of Bristol-Myers Squibb?
- What is the ticker symbol for Bristol-Myers Squibb?
- Does Bristol-Myers Squibb pay dividends?
- What sector is Bristol-Myers Squibb in?
- What industry is Bristol-Myers Squibb in?
- What country is Bristol-Myers Squibb based in?
- When did Bristol-Myers Squibb go public?
- Is Bristol-Myers Squibb in the S&P 500?
- Is Bristol-Myers Squibb in the NASDAQ 100?
- Is Bristol-Myers Squibb in the Dow Jones?
- When was Bristol-Myers Squibb's last earnings report?
- When does Bristol-Myers Squibb report earnings?
- Should I buy Bristol-Myers Squibb stock now?